Strong third quarter results - Revenue up 9% to ?10.5 million and net profit up 74% to ?0.6 million
(Thomson Reuters ONE) -
Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading
international family stem cell bank, announces its trading update for the
quarter ended 30 September 2011.
Financial highlights for the period were:
* Third quarter revenue up 9% to ?10.48 million (Q3 2010: ?9.61 million). For
the period to 30 September 2011, revenue was up 8% to ?31.60 million (30
September 2010: ?29.14 million)
* EBITA(*) up 7% to ?1.13 million (Q3 2010: ?1.06 million). For the period to
30 September 2011, EBITA was up 9% to ?3.86 million (30 September 2010:
?3.54 million)
* Operating profit of ?0.73 million (Q3 2010: ?0.75 million). For the period
to 30 September 2011, operating profit was up 3% to ?2.70 million (30
September 2010: ?2.61 million)
* Net profit up 74% to ?0.57 million (Q3 2010: ?0.33 million). For the period
to 30 September 2011, net profit was up 17% to ?1.86 million (30 September
2010: ?1.59 million)
* EBITA is defined as Earnings Before Interest, Taxation and Amortization of
identified intangible assets
Operational highlights for the period were:
* 10,000 new samples stored in Q3 2011, up 6% (Q3 2010: 9,400). Of these,
6,200 were new cord blood samples and 3,800 new cord tissue samples. For the
period to 30 September 2011, 29,600 new samples were stored, up 6% (30
September 2010: 27,900)
* 194,000 samples have now been stored in total
* 'FDA-ready' validation study of Cryo-Lip(® )completed in the US and
partnership with Texas-based Genesis Biosystems to market Cryo-Lip(®) in the
US
* State-of-the-art stem cell processing and storage laboratory opened in Cape
Town, South Africa
* Accreditation by Swissmedic, the Swiss government agency for therapeutic
products, confirming Cryo-Save's delivery of high quality, and safe and
effective procedures
* A six-year-old girl from Portugal with Cerebral Palsy was treated at Duke
University in the US with her own cord blood stem cells, stored and released
by Cryo-Save
Highlights after 30 September 2011 were:
* First stem cell bank in India to receive World Health Organisation - Good
Manufacturing Procedures (WHO-GMP) certification, guaranteeing the superior
quality, safety and effectiveness of the service
* Proactive contribution in increasing awareness of stem cell therapies and
regenerative medicine amongst healthcare professionals. Examples of these
were:
* Launch of the LIVECORD project with the Italian Association of Hospital
Obstetricians and Gynaecologists (AOGOI), dedicated to providing
education and accurate information on the cryopreservation of stem cells
and their uses in clinical therapeutic treatments to medical and
paramedical staff
* Participation and support of the International Symposium on Clinical
Applications of Stem Cell Therapies in Belgrade, Serbia where several
key researchers and scientists presented on topics regarding
transplantation, cord blood, heart disease and many other modern
clinical applications of stem cell therapies
* Attendance and sponsorship of the umbilical cord blood charity gala in
Bern, Switzerland, organized by Professor Surbek, one of the leading
gynaecologists in Switzerland
Arnoud van Tulder, Chief Executive officer, commented:
"We are pleased to report continued revenue growth along with solid returns,
allowing us to maintain our investment in the improvement and quality of our
services.
"The acceptance of our samples by treating physicians, the accreditation in
Switzerland and the certification in India are great endorsements of the quality
of our products and service. The enthusiasm of organisations such as Genesis
Biosystems in the US and AOGOI in Italy to partner with Cryo-Save demonstrates
our market leading position".
Enquiries:
Cryo-Save Group,
Arnoud van Tulder, Chief Executive Officer, + 31 (0) 575 548 998
SPJ Financiële Communicatie (The Netherlands),
Kees Jongsma/Leon Melens, +31 (0)20 647 8181
Daniel Stewart & Company plc (UK),
Sean Lunn, + 44 (0) 20 7776 6550
College Hill (UK),
Rozi Morris/ Adrian Duffield, + 44 (0) 20 7457 2020
Free footage is available on www.videobankonline.com.
About Cryo-Save (www.cryo-save.com/group)
Cryo-Save, the leading international family stem cell bank, already stores more
than 194,000 samples from cord blood and umbilical cord tissue for newborns and
adipose tissue for adults. These stem cells can mean the difference between life
and death in the case of future threats to the health of the donors. There are
already several diseases that can be cured by the use of stem cells, and the
number of treatments will only increase. The use of stem cells from adipose
tissue is increasingly popular in plastic surgery. Driven by its international
business strategy, Cryo-Save is now represented in over 40 countries on four
continents, with ultra-modern processing and storage facilities in the United
States, Belgium, Germany, Dubai, India, South Africa and France (validation in
progress).
Click here for full pres release in PDF:
http://hugin.info/143308/R/1559541/482299.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cryo-Save Group N.V. via Thomson Reuters ONE
[HUG#1559541]
Unternehmensinformation / Kurzprofil:
Datum: 01.11.2011 - 07:00 Uhr
Sprache: Deutsch
News-ID 82679
Anzahl Zeichen: 6463
contact information:
Town:
Zutphen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 143 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Strong third quarter results - Revenue up 9% to ?10.5 million and net profit up 74% to ?0.6 million"
steht unter der journalistisch-redaktionellen Verantwortung von
Cryo-Save Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
